The Latvian firm, Grindeks has made a few announcements recently which reveal the firm is aiming to expand its business. On 19th August, the firm reported that it was considering establishing injections manufacturing in Latvia, and was looking at the territory of Riga Free Port as a possible site to construct a new plant, because of economic incentives and tax allowances offered there. However, the firm added that purchasing an existing plant would also be an option. This was followed on 7th September with an announcement that the firm was considering options to develop its ointment business. Here, Grindeks is looking at two possibilities: either move its existing operations in Tallinn, Estonia, to Latvia, or remain in Tallinn, and presumably develop the plant there. As yet, no decision has been made.
Grindeks has, in recent years, been undertaking an investment programme, and these recent announcements are in line with that. In January 2009, the firm opened a new final dosage forms plant; the firm commented that this had been the largest investment project in the company's history, with LVL9.1 million (US$16.8 million) invested over two years. It is anticipated that the new plant will increase manufacturing productivity and capacity substantially, to 1.5 billion tablets and 500 million capsules per year.
Additionally, in August this year, Grindeks also announced that it had introduced a new active pharmaceutical ingredient, ursodeoxycholic acid, used in the treatment of hepatic and gallstone diseases. The new API represents a new medical therapeutic group for the firm, and has been developed as part of a co-operation agreement with the German firm, Marenis Pharma; once again evidence of Grindeks' plans to expand. The firm also announced it had started construction on a new manufacturing unit with an investment of nearly LVL6 million (US$12.5 million), connected with the development of this API. This again is an important move for the company; Germany is a relatively unexplored territory for Grindeks, whose traditional markets have been those of Central and Eastern Europe, the Baltic States and the CIS. Although Grindeks has co-operated with Merck in Germany, its presence there has been limited. The development of new APIs is of course also significant. Despite the economic turmoil of recent months, Grindeks appears to still be on course to expand its horizons.
Ian Platts – Editor, World Generic Markets
Friday, September 25, 2009
Tuesday, September 8, 2009
Canadian manufacturers squabble over statistics
Canada’s Patented Medicine Prices Review Board (PMPRB) has issued its Annual Report for 2008, leading to claims and counter-claims by the country’s generic and branded industry organisations. The Canadian Generic Pharmaceutical Association (CGPA) used the report to criticise the branded industry, noting that for the eighth year in a row, the branded industry had failed to reach its threshold of 10% of their Canadian revenues being ploughed into Domestic R&D spending; this having been a commitment made by the branded industry in 1987, with the adoption of amendments to the Patent Act. In response, Canada’s Research-Based Pharmaceutical Companies (Rx&D) has sought to play down the last eight years of failing to reach the target, arguing instead that its member companies’ total investments in R&D in Canada over the last 20 years has averaged more than 10% of sales. Of course, both sides are correct in their assertions, depending on how the data is analysed. It is worth noting also that the PMPRB’s report states that Rx&D members accounted for 89.4% of all reported R&D expenditures in 2008, with patentees reporting a total of C$1.3 billion (US$1.2 billion) of R&D expenditures.
However, whilst the overall average for the last 20 years is for over 10% of sales put into domestic R&D, the figures presented by the PMPRB’s report show that the branded industry only met and / or exceeded the 10% figure in eight years, between 1993 and 2000, whilst Rx&D member companies managed to meet and / or exceed the figure in ten years, between 1993 and 2002. Despite the occasional blip, the ratio figure has been falling since those years, having reached 8.1% for all patentees in 2008, and 8.9% for Rx&D members.
Rx&D brought attention to wider issues, noting that the PMPRB’s report also showed that whilst the Consumer Price Index climbed by 2.3% in Canada in 2008, prices for patented medicines rose by only 0.1% during the same period. The organisation added that over the past decade, prices for innovative medicines were around 7% below the international median. However, against that, the report also shows that Canadian prices were the third highest of seven comparator countries, behind only the US and Germany. However, the US was highest by some margin, skewing the figures somewhat.
The PMPRB’s report gives a detailed look at the state of the Canadian branded industry’s finances, but as always, its findings are open to interpretation of the statistics. The claims and counterclaims of both the branded and generic industries hold up when viewed in the right context, despite apparently being at odds with each other. Perhaps then, the value of the report is that it shows that both sides could do better.
Ian Platts - Editor, World Generic Markets
However, whilst the overall average for the last 20 years is for over 10% of sales put into domestic R&D, the figures presented by the PMPRB’s report show that the branded industry only met and / or exceeded the 10% figure in eight years, between 1993 and 2000, whilst Rx&D member companies managed to meet and / or exceed the figure in ten years, between 1993 and 2002. Despite the occasional blip, the ratio figure has been falling since those years, having reached 8.1% for all patentees in 2008, and 8.9% for Rx&D members.
Rx&D brought attention to wider issues, noting that the PMPRB’s report also showed that whilst the Consumer Price Index climbed by 2.3% in Canada in 2008, prices for patented medicines rose by only 0.1% during the same period. The organisation added that over the past decade, prices for innovative medicines were around 7% below the international median. However, against that, the report also shows that Canadian prices were the third highest of seven comparator countries, behind only the US and Germany. However, the US was highest by some margin, skewing the figures somewhat.
The PMPRB’s report gives a detailed look at the state of the Canadian branded industry’s finances, but as always, its findings are open to interpretation of the statistics. The claims and counterclaims of both the branded and generic industries hold up when viewed in the right context, despite apparently being at odds with each other. Perhaps then, the value of the report is that it shows that both sides could do better.
Ian Platts - Editor, World Generic Markets
Friday, August 21, 2009
Oxfam's fears over ACTA and generics
In a press release issued just before the fifth round of negotiations for the Anti-Counterfeiting Trade Agreement (ACTA) got under way in Morocco, Oxfam warned of its fears that the final agreement could lead to generic firms being subject to criminal prosecutions for sending generics to countries in need (see p. 4). However, the likelihood of such an outcome from ACTA is open to question. Of course, on the face of it, ACTA is not concerned with generic drug markets, or indeed the provision of legitimate drugs, whether branded or generic, to developing countries. According to the Office of the US Trade Representative, its roots lie in a desire to tackle the proliferation of counterfeit and pirated goods around the world. It sprung from preliminary talks in 2006 and 2007, with negotiations beginning in June 2008 involving Australia, Canada, the EU and its 27 member states, Japan, Mexico, Morocco, New Zealand, South Korea, Singapore, Switzerland and the US. The round of discussions in Morocco was the fifth round, with the next round to be held in Korea in November 2009. Negotiations are expected to be completed in 2010.
With regard to Oxfam’s fears, the organisation comments that the secrecy surrounding the talks raises fears that the interests of poorer nations will be ignored, and cites the EU’s recent seizures of generic medicines as evidence. Oxfam argues that the EU is taking the lead in pushing for a deal that would require all participating countries to increase seizures and prosecute companies which produce generics legally for sale in other countries. The organisation claims that this will include countries not directly involved in the negotiations, and notes that only two of the countries involved in negotiations are developing countries. Oxfam argues that this could encourage Big Pharma to file frivolous patents to maintain their monopolies.
The official line on the secrecy surrounding the talks is that this is an accepted practice during trade negotiations which allows views to be exchanged in confidence in order to arrive at a final consensus. The argument that multinational pharmaceutical companies would use the agreements to file ‘frivolous’ patents to prevent generics is questionable. Such a blatant attempt would be a public relations disaster, akin to the backlash seen with the South African patent laws debacle in 2001. It would also fly in the face of patent legislation seen in countries such as Canada, the EU and the US, which has sought to tackle such issues of evergreening. To be successful, ACTA will need to fit in with the existing TRIPS framework; the WTO has consistently been at pains to insist that TRIPS would not get in the way of sending generics to countries in need. However, it is fair to note, as Oxfam does, that EU member states have recently been seizing shipments of generics passing within its borders and headed to developing nations, often under suspicions of patent or trademark infringement, although the shipments have ultimately been allowed to continue their journeys. In addition, US free trade agreements passed in recent years have often been accused of being ‘TRIPS-plus’ in making extra demands regarding intellectual property rights that are not necessarily in line with TRIPS requirements. However, it seems unlikely that preventing shipments of generics would either be the intent or the outcome of the negotiations.
With regard to Oxfam’s fears, the organisation comments that the secrecy surrounding the talks raises fears that the interests of poorer nations will be ignored, and cites the EU’s recent seizures of generic medicines as evidence. Oxfam argues that the EU is taking the lead in pushing for a deal that would require all participating countries to increase seizures and prosecute companies which produce generics legally for sale in other countries. The organisation claims that this will include countries not directly involved in the negotiations, and notes that only two of the countries involved in negotiations are developing countries. Oxfam argues that this could encourage Big Pharma to file frivolous patents to maintain their monopolies.
The official line on the secrecy surrounding the talks is that this is an accepted practice during trade negotiations which allows views to be exchanged in confidence in order to arrive at a final consensus. The argument that multinational pharmaceutical companies would use the agreements to file ‘frivolous’ patents to prevent generics is questionable. Such a blatant attempt would be a public relations disaster, akin to the backlash seen with the South African patent laws debacle in 2001. It would also fly in the face of patent legislation seen in countries such as Canada, the EU and the US, which has sought to tackle such issues of evergreening. To be successful, ACTA will need to fit in with the existing TRIPS framework; the WTO has consistently been at pains to insist that TRIPS would not get in the way of sending generics to countries in need. However, it is fair to note, as Oxfam does, that EU member states have recently been seizing shipments of generics passing within its borders and headed to developing nations, often under suspicions of patent or trademark infringement, although the shipments have ultimately been allowed to continue their journeys. In addition, US free trade agreements passed in recent years have often been accused of being ‘TRIPS-plus’ in making extra demands regarding intellectual property rights that are not necessarily in line with TRIPS requirements. However, it seems unlikely that preventing shipments of generics would either be the intent or the outcome of the negotiations.
Friday, August 14, 2009
Battle lines drawn over biologic data exclusivity
The debate in the US Congress regarding the shape and form of a regulatory pathway for follow-on biologics has taken another step forward in recent months, with battle lines being drawn over the issue of how much of a data exclusivity period innovator biologics should be given. So far, the branded industry’s view is winning over the generic industry’s preference, although the latter is more in line with the White House’s thinking on the matter.
In March 2009, two competing bills were introduced to the House of Representatives concerning the establishment of a follow-on biologic pathway. Chronologically, the first was H.R. 1427, the Promoting Innovation and Access to Life-Saving Medicine Act, introduced by Representatives Henry Waxman, Frank Pallone, Nathan Deal and Jo Ann Emerson; this bill would give original biologics five years of exclusivity, whilst some modifications of existing drugs would get three years, with both periods having the potential to be extended by a year. Just a few days later, a second bill, H.R. 1548, the Pathway for Biosimilars Act, was introduced by Representatives Anna Eshoo, Jay Inslee and Joe Barton. Though the two bills were broadly similar, H.R. 1548 proposed providing up to 14 and a half years of data exclusivity for original biologics. Needless to say, the generic industry supports a shorter period of data exclusivity, whilst the branded industry as represented by BIO, the Biotechnology Industry Organisation, supports a longer period.
At first glance it would seem that H.R. 1427 would be more likely to succeed. Henry Waxman’s name carries weight in the field of generics, as one of the architects of the Hatch-Waxman Act which regulates conventional generics. In addition, Mr Waxman is now chairman of the House Energy and Commerce Committee, through which both bills must pass. Mr Waxman also wrote in June 2009 to the White House regarding a regulatory pathway, and the White House reply indicated a preference for seven years of data exclusivity following a report from the Federal Trade Commission which argued that the 12 to 14 years favoured by the branded industry would diminish innovation and unnecessarily delay generic alternatives.
However, it is becoming clear that a longer exclusivity period, such as that introduced by H.R. 1548, is more likely to become law. Crucially, the Senate HELP Committee voted on 13th July 2009 in favour of a 12-year period of exclusivity, with a vote 16-7 in favour. It also voted down an amendment which would have provided seven years, in line with the opinion of the White House. Welcoming the vote, BIO also noted that support for H.R. 1548 was growing in Congress. The organisation commented that H.R. 1548 had attracted 129 cosponsors, whilst H.R. 1427 had attracted only 13. At last count, H.R. 1548 had 142 cosponsors, whilst H.R. 1427 had 14, but the point is clear: supporters of a longer data exclusivity period outnumber by ten to one supporters of a shorter period. Interestingly, only one Representative, John Conyers, is listed as a cosponsor for both bills.
Organisations in support of a shorter period have dug in, and are already battling both to save H.R. 1427 and to scrap the 12-year period approved by the HELP Committee. Given the position of the White House, that battle is not yet lost, but the clear preference that is emerging from Congress must make the originator industry favourites in the fight.
In March 2009, two competing bills were introduced to the House of Representatives concerning the establishment of a follow-on biologic pathway. Chronologically, the first was H.R. 1427, the Promoting Innovation and Access to Life-Saving Medicine Act, introduced by Representatives Henry Waxman, Frank Pallone, Nathan Deal and Jo Ann Emerson; this bill would give original biologics five years of exclusivity, whilst some modifications of existing drugs would get three years, with both periods having the potential to be extended by a year. Just a few days later, a second bill, H.R. 1548, the Pathway for Biosimilars Act, was introduced by Representatives Anna Eshoo, Jay Inslee and Joe Barton. Though the two bills were broadly similar, H.R. 1548 proposed providing up to 14 and a half years of data exclusivity for original biologics. Needless to say, the generic industry supports a shorter period of data exclusivity, whilst the branded industry as represented by BIO, the Biotechnology Industry Organisation, supports a longer period.
At first glance it would seem that H.R. 1427 would be more likely to succeed. Henry Waxman’s name carries weight in the field of generics, as one of the architects of the Hatch-Waxman Act which regulates conventional generics. In addition, Mr Waxman is now chairman of the House Energy and Commerce Committee, through which both bills must pass. Mr Waxman also wrote in June 2009 to the White House regarding a regulatory pathway, and the White House reply indicated a preference for seven years of data exclusivity following a report from the Federal Trade Commission which argued that the 12 to 14 years favoured by the branded industry would diminish innovation and unnecessarily delay generic alternatives.
However, it is becoming clear that a longer exclusivity period, such as that introduced by H.R. 1548, is more likely to become law. Crucially, the Senate HELP Committee voted on 13th July 2009 in favour of a 12-year period of exclusivity, with a vote 16-7 in favour. It also voted down an amendment which would have provided seven years, in line with the opinion of the White House. Welcoming the vote, BIO also noted that support for H.R. 1548 was growing in Congress. The organisation commented that H.R. 1548 had attracted 129 cosponsors, whilst H.R. 1427 had attracted only 13. At last count, H.R. 1548 had 142 cosponsors, whilst H.R. 1427 had 14, but the point is clear: supporters of a longer data exclusivity period outnumber by ten to one supporters of a shorter period. Interestingly, only one Representative, John Conyers, is listed as a cosponsor for both bills.
Organisations in support of a shorter period have dug in, and are already battling both to save H.R. 1427 and to scrap the 12-year period approved by the HELP Committee. Given the position of the White House, that battle is not yet lost, but the clear preference that is emerging from Congress must make the originator industry favourites in the fight.
Tuesday, July 21, 2009
EC reports antitrust findings
In July 2009, the European Commission announced the findings of its report looking at the pharmaceutical sector. The report was initiated in January 2008, with its preliminary conclusions being announced the following November. The final report has concluded that generic entry in the European Union is being delayed and that there has been a decline in the number of new medicines reaching the market. The report suggested that company practices were amongst the causes, but accepted that other factors were also at play.
The Commission intends to follow the report up with intensified scrutiny of the pharmaceutical sector under EC antitrust laws. It added that certain acts initiated by originator companies would remain subject to competition scrutiny if they were being employed in an anti-competitive way in order to delay generic entry. In addition, defensive patenting strategies that focused on excluding competition without pursuing innovative efforts would also remain under scrutiny. The EC would also monitor agreements between originator and generic companies, in order that such agreements did not limit or delay market entry of generics.
The European Generic medicines Association (EGA) announced that it was welcoming the report, commenting that the final report took the initial findings from November 2008 to the next level. The organisation added that it and its members had worked closely with the EC, seeing the report as an opportunity to address what it considered to be loopholes in the legislative framework. The EGA added that it was urging EU member states to implement the recommendations of the report quickly. Perhaps unsurprisingly, the European Federation of Pharmaceutical Industries and Associations (EFPIA) was less welcoming. However, looking for positives in the report for the branded industry, the EFPIA commented that the final report had represented a welcome shift away from what it had considered to be emotive language used in the preliminary findings. The EFPIA made the argument that it had consistently found that regulatory barriers were causing problems for both the generic and branded industries alike in Europe, adding that it was pleased that the report had backed this up. The organisation added that it welcomed many of the report’s recommendations, including creating a streamlined patent system, which would obviously be of benefit to the branded industry. However, the EFPIA commented that the Commission should use the report to address the issue of competition in the off-patent market, arguing that this was an area which could be reformed to produce savings. These savings could then be reinvested to fund innovative medicines, an idea which would probably not go down well with the EGA.
The EC has been able to produce a report that has something for both the generic and branded industries to take comfort from. The question now will be whether or not the EC will be able to turn the report’s recommendations into actions.
Ian Platts - Editor, World Generic Markets
The Commission intends to follow the report up with intensified scrutiny of the pharmaceutical sector under EC antitrust laws. It added that certain acts initiated by originator companies would remain subject to competition scrutiny if they were being employed in an anti-competitive way in order to delay generic entry. In addition, defensive patenting strategies that focused on excluding competition without pursuing innovative efforts would also remain under scrutiny. The EC would also monitor agreements between originator and generic companies, in order that such agreements did not limit or delay market entry of generics.
The European Generic medicines Association (EGA) announced that it was welcoming the report, commenting that the final report took the initial findings from November 2008 to the next level. The organisation added that it and its members had worked closely with the EC, seeing the report as an opportunity to address what it considered to be loopholes in the legislative framework. The EGA added that it was urging EU member states to implement the recommendations of the report quickly. Perhaps unsurprisingly, the European Federation of Pharmaceutical Industries and Associations (EFPIA) was less welcoming. However, looking for positives in the report for the branded industry, the EFPIA commented that the final report had represented a welcome shift away from what it had considered to be emotive language used in the preliminary findings. The EFPIA made the argument that it had consistently found that regulatory barriers were causing problems for both the generic and branded industries alike in Europe, adding that it was pleased that the report had backed this up. The organisation added that it welcomed many of the report’s recommendations, including creating a streamlined patent system, which would obviously be of benefit to the branded industry. However, the EFPIA commented that the Commission should use the report to address the issue of competition in the off-patent market, arguing that this was an area which could be reformed to produce savings. These savings could then be reinvested to fund innovative medicines, an idea which would probably not go down well with the EGA.
The EC has been able to produce a report that has something for both the generic and branded industries to take comfort from. The question now will be whether or not the EC will be able to turn the report’s recommendations into actions.
Ian Platts - Editor, World Generic Markets
Friday, June 19, 2009
FTC releases follow-on biologic competition report
The Federal Trade Commission released a report on 10th June 2009 investigating the potential effects of follow-on biologic drug competition. The report concluded that developing a regulatory pathway to allow follow-on biologics would be an efficient way to bring lower-priced drugs to the market; this is not the most surprising conclusion that could be reached. However, the report did find that even with such a pathway, the competitive market between pioneer biologics and follow-on biologics would not be likely to follow the same course as the competitive market between branded and generic small molecule drugs, as fostered by the Hatch-Waxman Act. Follow-on biologics would be unlikely to enter the market for products with annual revenues less than US$250 million, and it would be likely that only two or three generic manufacturers would attempt entry for a given pioneer drug. Furthermore, given the costs involved in producing a follow-on product, drugs would be introduced with discounts no larger than between 10% and 30% of the pioneer’s product price. As a result, the pioneer could still expect to retain between 70% and 90% of market share, a far cry from the situation with traditional drugs, when generic entry can reduce market share by similar percentages as the FTC is estimating will be retained.
In that respect, the report does not seem to contain much bad news for the biologic drug industry. However, the industry’s association, BIO, responded to the report by saying that at first glance it was fundamentally flawed, and demonstrating a lack of understanding of the conditions necessary to drive biomedical innovation. This seems a somewhat surprising response to a report that suggests generic competition would not be as damaging to profits for the biologic industry as it has been for traditional medicines, with few competitors and relatively small price discounts. However, the cause of most concern may well reside in the report’s argument that a 12 to 14 year regulatory exclusivity period, as recommended in one of two bills in Congress attempting to create a regulatory pathway for follow-on biologics, would be too long to promote innovation. This appears to be a sticking point for BIO, which argues that even with the limited generic competition suggested by the report, other studies show that pioneer companies would be unable to recoup their costs without a 12 to 14 year exclusivity period. BIO claims to support the development of a regulatory pathway for follow-on biologics, and with two competing bills currently going through Congress to create a pathway, the question is more and more ‘when’ rather than ‘if’. However, as BIO’s response to this report shows, the biologic industry is determined over what form of pathway it will tolerate. The question will be how well the industry will fare in convincing Congress to agree with it.
Ian Platts - Editor, World Generic Markets
In that respect, the report does not seem to contain much bad news for the biologic drug industry. However, the industry’s association, BIO, responded to the report by saying that at first glance it was fundamentally flawed, and demonstrating a lack of understanding of the conditions necessary to drive biomedical innovation. This seems a somewhat surprising response to a report that suggests generic competition would not be as damaging to profits for the biologic industry as it has been for traditional medicines, with few competitors and relatively small price discounts. However, the cause of most concern may well reside in the report’s argument that a 12 to 14 year regulatory exclusivity period, as recommended in one of two bills in Congress attempting to create a regulatory pathway for follow-on biologics, would be too long to promote innovation. This appears to be a sticking point for BIO, which argues that even with the limited generic competition suggested by the report, other studies show that pioneer companies would be unable to recoup their costs without a 12 to 14 year exclusivity period. BIO claims to support the development of a regulatory pathway for follow-on biologics, and with two competing bills currently going through Congress to create a pathway, the question is more and more ‘when’ rather than ‘if’. However, as BIO’s response to this report shows, the biologic industry is determined over what form of pathway it will tolerate. The question will be how well the industry will fare in convincing Congress to agree with it.
Ian Platts - Editor, World Generic Markets
Friday, June 12, 2009
Sandoz acquires Ebewe; Pfizer expands generics agreements
Sandoz’ parent company, Novartis, announced on 20th May 2009 that it was to acquire the specialty generic injectables business of Ebewe Pharma, which would provide Sandoz an opportunity to create a global platform for future growth whilst improving access for patients worldwide to many generic oncology medicines. Under the terms of the deal, Novartis will acquire the business for 925 million euros (US$1.3 billion) in cash; the deal will exclude Ebewe’s separate injectable neurological products business. Sandoz is currently the second largest generic firm in the world, but still some way behind Teva Pharmaceutical Industries in terms of sales. According to Novartis, Ebewe Pharma’s net sales in 2008 were worth 188 million euros (US$267 million), so this acquisition is unlikely to see Sandoz push ahead past Teva. However, this is the firm’s first acquisition in a number of years, which must underline the firm’s belief that Ebewe represents a significant strategic fit.
Ebewe Pharma was founded in Vienna, Austria, in 1934, but relocated its headquarters to Unterach, Austria, in 1945. Between 1956 and 2001, it acted as an affiliate of the BASF Group, and also briefly for Abbott. However, in 2001, the company again became independent. The company specialises in technologies and applications in the fields of specialty pharmaceuticals, neurological products and contract manufacturing. With regard to its specialty products, the firm has focused on the categories of oncology and immunology, and claims to be one of the leading suppliers of parenteral specialty pharmaceuticals. Ebewe has research centres in Austria and the US, and the firm claims that in the area of oncology it offers one of the widest product lines in the industry. Ebewe sells its specialty pharmaceuticals through a network of 20 Ebewe country organisations as well as business partners in over 80 countries. The firm has had nine ANDAs approved in the US recently, between December 2007 and April 2009, with most of them being either CNS drugs or oncology drugs, including paclitaxel and methotrexate sodium.
Separately, but on the same day, Pfizer announced plans to expand its generics portfolio through two agreements with the Indian firm, Aurobindo Pharma and Claris Lifesciences. Pfizer previously entered into agreements with Aurobindo in July 2008 and March 2009, and this latest announcement effectively extends those into new areas. However, the agreement with Claris is new. Under the terms of the agreement, Pfizer has acquired the rights to 15 injectable products covering a number of therapeutic categories, including pain management and anti-infectives. Claris focuses on the production of injectables and claims a presence in over 76 countries. As with Ebewe, Claris has been active in the US generics market in recent years, gaining four ANDA approvals in March and April 2008 for ondansetron, ciprofloxacin and metronidazole. These agreements are an interesting move for Pfizer, which, although has a generics subsidiary in the form of Greenstone, has tended to be more averse to the generics industry than other branded pharmaceutical firms. Pfizer’s keenness to develop its presence in the generics market perhaps reflects difficulties the firm has seen with the branded industry in recent years. Although it has retained its position as the leading branded firm, Pfizer’s sales have been flat for the last few years, with increased generic competition for some of its key products sapping sales.
Ian Platts - Editor, World Generic Markets
Ebewe Pharma was founded in Vienna, Austria, in 1934, but relocated its headquarters to Unterach, Austria, in 1945. Between 1956 and 2001, it acted as an affiliate of the BASF Group, and also briefly for Abbott. However, in 2001, the company again became independent. The company specialises in technologies and applications in the fields of specialty pharmaceuticals, neurological products and contract manufacturing. With regard to its specialty products, the firm has focused on the categories of oncology and immunology, and claims to be one of the leading suppliers of parenteral specialty pharmaceuticals. Ebewe has research centres in Austria and the US, and the firm claims that in the area of oncology it offers one of the widest product lines in the industry. Ebewe sells its specialty pharmaceuticals through a network of 20 Ebewe country organisations as well as business partners in over 80 countries. The firm has had nine ANDAs approved in the US recently, between December 2007 and April 2009, with most of them being either CNS drugs or oncology drugs, including paclitaxel and methotrexate sodium.
Separately, but on the same day, Pfizer announced plans to expand its generics portfolio through two agreements with the Indian firm, Aurobindo Pharma and Claris Lifesciences. Pfizer previously entered into agreements with Aurobindo in July 2008 and March 2009, and this latest announcement effectively extends those into new areas. However, the agreement with Claris is new. Under the terms of the agreement, Pfizer has acquired the rights to 15 injectable products covering a number of therapeutic categories, including pain management and anti-infectives. Claris focuses on the production of injectables and claims a presence in over 76 countries. As with Ebewe, Claris has been active in the US generics market in recent years, gaining four ANDA approvals in March and April 2008 for ondansetron, ciprofloxacin and metronidazole. These agreements are an interesting move for Pfizer, which, although has a generics subsidiary in the form of Greenstone, has tended to be more averse to the generics industry than other branded pharmaceutical firms. Pfizer’s keenness to develop its presence in the generics market perhaps reflects difficulties the firm has seen with the branded industry in recent years. Although it has retained its position as the leading branded firm, Pfizer’s sales have been flat for the last few years, with increased generic competition for some of its key products sapping sales.
Ian Platts - Editor, World Generic Markets
Subscribe to:
Posts (Atom)